A preclinical study reported that novel PARP inhibitor No. 123 suppressed cervical tumor progression in mice by combining direct cytotoxicity with immune activation through the cGAS-STING pathway. The findings position PARP inhibition as a possible immunology-forward strategy for solid tumors, with mechanism-specific effects beyond DNA repair blockade.